Alphamab Oncology, 3DMed start Phase III for PD-L1 antibody in cholangiocarcinoma

Alphamab Oncology (Suzhou, China) and 3D Medicines Corp. (Shanghai, China) began a Phase III trial of KN035 plus gemcitabine and oxaliplatin to treat cholangiocarcinoma.

The open-label, Chinese trial will enroll about 390 patients. The trial's primary endpoint is overall survival (OS)...